Tablets & Capsules Magazine

Verified
Magazine
Tablets & Capsules is a controlled-circulation trade magazine in print since 2003. It provides practical information about the formulation, production, and packaging of solid dosage forms, including powders, gums, and films. Our technical articles focus on the materials, processes, and equipment used to make solid dosage forms. The articles examine what’s new, offer troubleshooting advice, discuss equipment selection, provide formulation guidance, and show how companies have resolved their process problems. T&C’s 10,000+ readers take part in every activity related to solid dosage forms, from R&D and product development to commercial manufacture and quality assurance. Source

Actions

Share this page

Media Outlet details

Scope National, Trade/B2B
Language English
Country United States of America
Similarweb UVMSimilarweb UVM Request pricing
Comscore UVMComscore UVM Request pricing
Frequency Monthly

Recent Articles

Search

Insilico Advances AI-Empowered TNIK Inhibitor into Phase 3

| Tablets & Capsules Magazine Verified
Insilico has announced that it is starting a phase 3 clinical trial for rentosertib, a drug that could be a first-in-class oral small-molecule inhibitor for idiopathic pulmonary fibrosis (IPF). Rentosertib was discovered and designed by Pharma.AI, Insilico’s AI platform for aging biology. The novel target was prioritized by the company’s AI-powered biology engine, Biology42: PandaOmics.
Open in Who Shared Issue with article?

Data in Hand, Compass Psychedelic on Track for Q4 NDA Submission

| Tablets & Capsules Magazine Verified
Compass Pathways announced 26-week results (Part B) from its second ongoing phase 3 COMP006 trial of COMP360, a synthetic, proprietary formulation of psilocybin, for treatment-resistant depression (TRD), confirming the drug’s rapid onset and durable profile. The 26-week findings in nearly 600 patients build on previously reported results from the first phase 3 trial, COMP005, which also demonstrated rapid onset and durable response to at least 6 months.
Open in Who Shared Issue with article?

FDA Accepts Pharvaris NDA for Oral HAE Drug

| Tablets & Capsules Magazine Verified
Pharvaris has announced that the U.S. FDA has accepted its NDA for deucrictibant IR capsules to treat hereditary angioedema (HAE) attacks, with a PDUFA action date set for April 23, 2027. Deucrictibant is a novel, oral bradykinin B2 receptor antagonist that received orphan drug designation from the FDA in 2022. If approved, it will become the first such drug to treat HAE attacks.
Open in Who Shared Issue with article?

Vertex to Buy Crinetics for $10B

| Tablets & Capsules Magazine Verified
Vertex Pharmaceuticals has announced that it is purchasing Crinetics Pharmaceuticals, gaining best-in-class commercialized and phase 3 endocrinology assets. Vertex is acquiring Crinetics for $85.00 per share in cash, which has an equity value of approximately $10.0 billion or $8.8 billion net of estimated cash acquired. Crinetics recently received FDA approval for Palsonify (paltusotine), the only once-daily, oral therapy for adults with acromegaly.
Open in Who Shared Issue with article?

NEJM Retracts Pivotal Publication for Amgen’s Tavneos

| Tablets & Capsules Magazine Verified
The New England Journal of Medicine has retracted a pivotal publication supporting the approval of Amgen's oral C5a receptor inhibitor, Tavneos, at the request of two of the study's academic authors. The authors requested the retraction after alleging that, without their knowledge, the primary endpoint assessments for nine patients were re-adjudicated after the trial database had been locked and unblinded.
Open in Who Shared Issue with article?

Creating Amorphous Solid Dispersions via Spray Drying

|
By João Henriques, Patricia Cruz
| Tablets & Capsules Magazine Verified
The majority of molecules in the drug development pipeline fall into Biopharmaceutical Classification System (BCS) Class II or IV, exhibiting poor aqueous solubility that limits active pharmaceutical ingredient (API) bioavailability. This challenge is often addressed by creating amorphous solid dispersions (ASDs) of the API in a polymeric matrix using either thermal methods, such as hot-melt extrusion, or solvent-based methods, such as spray drying.
Open in Who Shared Issue with article?

When AI Isn't Enough

|
By Dean Cirotta
| Tablets & Capsules Magazine Verified
Artificial intelligence (AI) is increasingly being integrated into FDA regulated industries, where it is used to process large volumes of data, create documents, generate reports, analyze results, enhance search functions and support decision-making. The FDA defines AI as the science and engineering of creating intelligent machines capable of performing tasks that typically require human intelligence.
Open in Who Shared Issue with article?

Otsuka Novel ADHD Drug Posts Phase 3 Win

| Tablets & Capsules Magazine Verified
Otsuka Pharmaceutical Co.has announced positive results in a phase 3b study of its oral drug, centanafadine, to reduce the symptoms of attention deficit/hyperactivity disorder (ADHD) and comorbid anxiety in adults. Centanafadine is a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor (NDSRI).
Open in Who Shared Issue with article?

STADA Buys Consumer Health Portfolio from Orifarm

| Tablets & Capsules Magazine Verified
STADA has announced that it is acquiring Orifarm’s healthcare portfolio, gaining the company 16 vitamin, mineral, and supplement (VMS) brands and subsequently driving its growth in Europe. Already a leading consumer healthcare company, the acquisition will boost STADA’s position in Belgium, Poland, and the Nordics. The move is in line with the company’s aim to add brands that are leading in national and regional markets to its portfolio.
Open in Who Shared Issue with article?

Calico Gets Breakthrough Therapy Tag for Ultra-Rare Brain Disease Drug

| Tablets & Capsules Magazine Verified
Calico Life Sciences has received breakthrough therapy designation from the FDA for fosigotifator to treat vanishing white matter (VWM) disease, a rare, inherited neurological disorder. Fosigotifator is an investigational, orally-active, brain penetrant, eIF2B activator. By targeting a translation initiation factor, it reduces enzymatic activity that leads to the chronic activation of the integrated stress response (ISR).
Open in Who Shared Issue with article?